Human Chronic Myeloid Leukemia Peripheral Blood Mononuclear Cells (Accelerated/Blast Crisis)

Description

Human Chronic Myeloid Leukemia Peripheral Blood Mononuclear Cells (CML PBMCs) (Accelerated/Blast Crisis) (accelerated blast) are primary cells isolated from CML patients in advanced disease stages, providing a critical model for studying disease progression and therapeutic resistance. These PBMCs contain increased numbers of immature myeloid blasts (CD34⁺/CD38⁻) alongside characteristic Philadelphia chromosome-positive (BCR-ABL1⁺) leukemic cells, often with additional genetic abnormalities such as trisomy 8, isochromosome 17q, or TP53 mutations that drive aggressive transformation. The functional abnormality of these PBMCs is manifested by the continuous activation of tyrosine kinase driven by the BCR-ABL1 fusion gene, which regulates the cell cycle through signaling pathways such as Ras and PI3K, inhibits apoptosis and promotes proliferation. The accelerated/blast crisis phenotype of these cells makes them particularly valuable for investigating tyrosine kinase inhibitor (TKI) resistance mechanisms, genomic instability, and the molecular basis of disease evolution from chronic phase. This accelerated blast phenotype closely mirrors advanced clinical CML, enabling detailed analysis of leukemic stem cell expansion, clonal evolution, and treatment failure in late-stage disease.